GlassScriptPhysician profile
Charles Villoch
NPI 1437251899
$25,587.55
in general payments reported to CMS, 2019-2025
22 companies · $958 in 2025
The $958 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,171 · 2020: $2,843 · 2021: $5,326 · 2022: $3,556 · 2023: $3,280 · 2024: $4,454 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,942 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,942.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15,342.15 | 2019-2025 | Lifevest |
| Irhythm Technologies, INC. | $1,320.10 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $1,180.50 | 2019-2024 | Xarelto |
| Abbott Laboratories | $1,169.19 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,143.89 | 2019-2025 | Brilinta, Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $1,097.35 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $856.73 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $818.08 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $741.70 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $594.00 | 2019-2025 | Jardiance |
| Pfizer INC. | $446.93 | 2019-2025 | |
| Novo Nordisk INC | $256.41 | 2023-2025 | Wegovy, Ozempic |
| Amarin Pharma, INC. | $226.22 | 2019-2021 | |
| Inspire Medical Systems, INC. | $118.22 | 2024 | Inspire |
| Medtronic Vascular, INC. | $61.95 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $55.98 | 2023-2024 | Bodyguardian, Watchman Flx |
| Edwards Lifesciences Corporation | $45.70 | 2025 | |
| Bridgebio Pharma, INC. | $41.92 | 2025 | Attruby |
| Baxter Healthcare | $19.70 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Bayer Healthcare Pharmaceuticals INC. | $18.78 | 2025 | |
| Abbvie INC. | $17.13 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.92 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Villoch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.